Ghidurile ESC - Media Med Publicis

162. Deleted in proof.
163. Deleted in proof.
164. Secondary prevention in non-rheumatic atrial fibrillation
after transient ischaemic attack or minor stroke. EAFT
(European Atrial Fibrillation Trial) Study Group. Lancet
1993;342:1255–62.
165. Hart RG, Benavente O, McBride R, et al. Antithrombotic
therapy to prevent stroke in patients with atrial fibrillation: a
meta-analysis. Ann Intern Med 1999;131:492–501.
166. Hylek EM, Singer DE. Risk factors for intracranial
hemorrhage in outpatients taking warfarin. Ann Intern Med
1994;120:897–902.
167. Ode´n A, Fahle´n M, Hart RG. Optimal INR for
prevention of stroke and death in atrial fibrillation: a critical
appraisal. Thromb Res 2006;117:493–9
168. Fihn SD, Callahan CM, Martin DC, et al. The risk for and
severity of bleeding complications in elderly patients treated
with warfarin. The National Consortium of Anticoagulation
Clinics. Ann Intern Med 1996;124:970–9.
169. Fang MC, Chang Y, Hylek EM, et al. Advanced age,
anticoagulation intensity, and risk for intracranial hemorrhage
among patients taking warfarin for atrial fibrillation. Ann
Intern Med 2004;141:745–52.
170. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of
oral anticoagulation on stroke severity and mortality in atrial
fibrillation. N Engl J Med 2003;349:1019–26.
171. Hart RG, Tonarelli SB, Pearce LA. Avoiding central
nervous system bleeding during antithrombotic therapy: recent
data and ideas. Stroke 2005;36:1588–93.
172. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs.
warfarin for stroke prevention in patients with nonvalvular
atrial fibrillation: a randomized trial. JAMA 2005;293:690–8.
173. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of
the lowest effective intensity of prophylactic anticoagulation
for patients with nonrheumatic atrial fibrillation. N Engl J
Med 1996;335:540–6.
174. Gullov AL, Koefoed BG, Petersen P. Bleeding during
warfarin and aspirin therapy in patients with atrial fibrillation:
the AFASAK 2 study. Atrial Fibrillation Aspirin and
Anticoagulation. Arch Intern Med 1999;159:1322–8.
175. Hellemons BS, Langenberg M, Lodder J, et al. Primary
prevention of arterial thromboembolism in non-rheumatic
atrial fibrillation in primary care: randomised controlled trial
comparing two intensities of coumarin with aspirin. BMJ
1999;319:958–64.
176. Warfarin versus aspirin for prevention of
thromboembolism in atrial fibrillation: Stroke Prevention in
Atrial Fibrillation II Study. Lancet 1994;343:687–91.
177. Diener HC, Cunha L, Forbes C. et al. European Stroke
Prevention Study-2 (ESPS-2). Dipyridamole and
acetylsalicylic acid in the secondary prevention of stroke. J
Neurol Sci 1996;143:1–13.
178. European Stroke Prevention Study. ESPS Group. Stroke
1990;21:1122–30.
179. Posada IS, Barriales V. Alternate-day dosing of aspirin in
atrial fibrillation. LASAF Pilot Study Group. Am Heart J
1999;138:137–43.
180. Farrell B, Godwin J, Richards S, et al. The United
Kingdom transient ischaemic attack (UK-TIA) aspirin trial:
final results. J Neurol Neurosurg Psychiatry 1991;54:1044–54.
181. The efficacy of aspirin in patients with atrial fibrillation.
Analysis of pooled data from 3 randomized trials. The Atrial
Fibrillation Investigators. Arch Intern Med 1997;157:1237–40.
182. Deleted in proof.
183. Hart RG, Benavente O, Pearce LA. Increased risk of
intracranial hemorrhage when aspirin is combined with
warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis
1999;9:215–7.
184. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and
efficacy of enoxaparin compared with unfractionated heparin
and oral anticoagulants for prevention of thromboembolic
complications in cardioversion of nonvalvular atrial
fibrillation: the Anticoagulation in Cardioversion using
Enoxaparin (ACE) trial. Circulation 2004;109:997–1003.
185. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin
and low-molecular-weight heparin: mechanisms of action,
pharmacokinetics, dosing, monitoring, efficacy, and safety.
Chest 2001;119:64S–94S.
186. Murray RD, Deitcher SR, Shah A, et al. Potential clinical
efficacy and cost benefit of a transesophageal
echocardiography-guidedlow-molecular-weight heparin
(enoxaparin) approach to antithrombotic therapy in patients
undergoing immediate cardioversion from atrial fibrillation. J
Am Soc Echocardiogr 2001;14:200–8.
187. Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic
therapy in patients with mechanical and biological prosthetic
heart valves. Chest 2001;119:220S–7S.
188. Blackshear JL, Johnson WD, Odell JA, et al.
Thoracoscopic extracardiac obliteration of the left atrial
appendage for stroke risk reduction in atrial fibrillation. J Am
Coll Cardiol 2003;42:1249–52.
189. Ostermayer SH, Reisman M, Kramer PH, et al.
Percutaneous left atrial appendage transcatheter occlusion
(PLAATO system) to prevent stroke in high-risk patients with
non-rheumatic atrial fibrillation: results from the international
multi-center feasibility trials. J Am Coll Cardiol 2005;46:9–
14.
190. Halperin JL, Gomberg-Maitland M. Obliteration of the
left atrial appendage for prevention of thromboembolism. J
Am Coll Cardiol 2003;42:1259–61.
191. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of
class IC antiarrhythmic drugs for acute conversion of
paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am
Coll Cardiol 1990;16:1722–7.
192. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol
versus verapamil in the acute treatment of atrial fibrillation or
atrial flutter. Am J Cardiol 1989;63:925–9.
193. Azpitarte J, Alvarez M, Baun O, et al. Value of single
oral loading dose of propafenone in converting recent-onset
atrial fibrillation. Results of a randomized, double-blind,
controlled study. Eur Heart J 1997;18:1649–54.
194. Kochiadakis GE, Igoumenidis NE, Solomou MC, et al.
Efficacy of amiodarone for the termination of persistent atrial
fibrillation. Am J Cardiol 1999;83:58–61.
195. Capucci A, Boriani G, Rubino I, et al. A controlled study
on oral propafenone versus digoxin plus quinidine in
converting recent onset atrial fibrillation to sinus rhythm. Int J
Cardiol 1994;43:305–13.
196. Vaughan Williams EM. A classification of
antiarrhythmic actions reassessed after a decade of new drugs.
J Clin Pharmacol 1984;24:129–47.
197. Falk RH, Pollak A, Singh SN, et al. Intravenous
dofetilide, a class III antiarrhythmic agent, for the termination
of sustained atrial fibrillation or flutter. Intravenous Dofetilide
Investigators. J Am Coll Cardiol 1997;29:385–90.
198. Norgaard BL, Wachtell K, Christensen PD, et al.
Efficacy and safety of intravenously administered dofetilide in
acute termination of atrial fibrillation and flutter: a
multicenter, randomized, double-blind, placebo-controlled
trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study
Group. Am Heart J 1999;137:1062–9.
199. Sedgwick ML, Lip G, Rae AP, et al. Chemical
cardioversion of atrial fibrillation with intravenous dofetilide.
Int J Cardiol 1995;49:159–66.
200. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.
Dofetilide in patients with congestive heart failure and left
ventricular dysfunction. Danish Investigations of Arrhythmia
56